First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)

Karen A Autio ,Stephane Billotte ,Megan M Kaneda ,Szu-Yu Tang ,Leonard Joseph Appleman ,Helen Cho ,Nora Cavazos ,Ravi A Madan ,Sandip M Prasad ,Hani M Babiker ,Celestia S Higano ,Ray Li ,Michael T Schweizer ,Nicholas J Vogelzang ,Jenny Zheng ,Orlaith Bogg ,Robert E Hollingsworth ,Tian Zhang ,Kam Ming Chan ,Xinhua Zhu ,Luke T Nordquist ,Kenneth A Kern ,I‐Ming Wang ,Daniel P Petrylak

doi:10.1136/jitc-2022-005702

Abstract

BackgroundThis phase 1 study evaluated PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in two clinical states of prostate cancer (PC), metastatic castration-resistant PC (mCRPC) and biochemical recurrence (BCR).MethodsFor dose escalation,...

Full Text